Phases of drug discovery and development process powerpoint presentation slides

So first you gotta identify your target - basically picking which protein or pathway you want to mess with for whatever disease you're tackling. Target validation comes next, where you actually prove that hitting this thing will help patients. Honestly, this is where tons of projects crash and burn. Then you do hit identification through screening to find compounds that actually interact with your target. After that it's all about optimizing those hits into something workable. The whole process is like a giant funnel - you start with thousands of possibilities and keep filtering down until you've got maybe a handful worth chasing.

Start by mapping out the biological pathways for your disease - you're hunting for proteins that are both druggable and actually matter for the disease process. Enzymes and receptors are usually good bets since blocking them can interrupt the whole pathological mess. Bioinformatics tools help predict which targets will be total nightmares versus accessible ones (honestly saved me so much time when I was doing this). The sweet spot? Find something essential for disease but not critical for normal cell function - easier said than done though. Check out KEGG or Reactome databases for your specific area first.

So HTS is like having robots test thousands of compounds against your protein target - way faster than doing it by hand. Most pharma companies run these screening robots 24/7 because honestly, testing each compound manually would take years. You're hunting for "hits" that show some biological activity worth digging into later. Yeah, tons of them end up being garbage or false positives, but at least you've got leads to work with. Without this automated approach, you'd basically be throwing darts blindfolded hoping something sticks. It's not perfect but it beats the alternative.

So computational screening is honestly a game-changer - you can test millions of compounds without touching a single test tube. Machine learning helps you pick winners from huge databases, and molecular modeling shows how well stuff binds to your target protein. ADMET modeling (absorption, distribution, metabolism, excretion, toxicity - yeah it's a mouthful) weeds out the duds early. That alone saves you from months of headaches later. You'll cycle through designs in days instead of months. My advice? Define your target first, then let the computers do the heavy lifting before you start any actual lab work.

So basically small molecules are the simple stuff - think pills you pop like aspirin. They're cheap to make and develop pretty fast. Biologics are these huge, complicated proteins that living cells have to produce, which is honestly a pain. You'll need injections for most of them. Development takes forever with biologics since manufacturing gets super tricky, plus you need special storage. But here's the thing - they can hit targets that small molecules literally can't touch. Less competition too since making biosimilars is way harder than generics. Really depends on what you're going after. Simple target? Go small molecule. Complex disease? You're probably looking at biologics.

You basically know the exact 3D shape you're targeting, so you can design drugs like fitting puzzle pieces instead of blindly testing thousands of random compounds. Way more efficient than the old spray-and-pray method. First thing - get solid crystal structure data of your protein target, that's your roadmap. Then you can actually see where molecules need to fit and design them accordingly. Hit rates go way up since you're not just guessing anymore. It's kinda wild how much time this saves compared to traditional screening approaches.

Patient safety has to be your top priority - don't mess around with informed consent. Animal testing is tricky ethically, so look for alternatives wherever you can. The access thing is massive too. Will people who actually need this drug be able to get it? Because honestly, pharmaceutical pricing is kind of a nightmare right now. Manufacturing creates environmental waste you'll need to deal with. Oh, and get an ethics committee involved from day one - they'll save you headaches later. Trust me on that one.

Dude, this is literally everything. Pick a crappy lead compound and you're screwed for the next 2-3 years - I've watched entire teams go down that rabbit hole. The ADMET properties matter way more than people think. Bad pharmacokinetics? You'll be optimizing forever while burning cash. Good leads with decent tox profiles and synthetic accessibility just move through preclinical so much smoother. Be super picky upfront, even if it feels harsh. Trust me, fixing a fundamentally broken compound later is a nightmare you don't want.

Look, safety and efficacy are gonna be your worst nightmares. Something kicks ass in the lab but then kills mice? Yeah, that happens constantly. Dosing gets weird, absorption's terrible, or it just doesn't work in real bodies. Plus the FDA keeps moving goalposts - super fun. I swear like 95% of drug candidates crash and burn somewhere along the way. Oh, and budget for twice as long as you think because your main compound will probably face-plant. Keep backup options ready. Trust me on this one, pharmaceutical development is basically expensive gambling with really bad odds.

Demographics matter way more than people think in drug discovery. Different groups metabolize stuff totally differently - like how certain Asian populations process some meds weird because of enzyme differences. Age and gender play into it too, obviously. The FDA now makes you have diverse trial participants, which is smart but should've happened ages ago honestly. Oh, and don't wait until your trials are already running to think about this stuff. Factor it in early when you're picking targets - way cheaper than scrambling later when everything's already set up.

Ugh, regulatory approval is such a pain - we're talking 10-15 years added to your timeline. Preclinical studies alone take 2-6 years, then you've got three clinical trial phases (another 6-7 years), plus FDA review which can drag on for months or even two years. That's assuming nothing goes wrong, which... yeah right. Failed trials basically mean you're back to square one or scrambling to pivot. Oh, and always keep backup compounds ready because something will definitely go sideways. Plan for these delays from the start or you'll hate yourself later.

So these partnerships are pretty smart when you think about it. Academic researchers can chase wild ideas that might not pay off for years - stuff that would make pharma executives nervous about their quarterly reports. But then industry swoops in with actual money and regulatory know-how. Universities excel at that messy early research phase. Companies know how to deal with FDA bureaucracy and scaling production (which honestly sounds like a nightmare). My advice? Find partners who fill your weak spots, not ones doing exactly what you're already doing well.

Honestly, AI and machine learning are total game-changers right now - you can predict which compounds will actually work before wasting time synthesizing them. CRISPR's huge too for disease models. But the thing that blew my mind recently was organ-on-a-chip tech. You're literally testing drugs on tiny human organs instead of just animal models. Pretty wild stuff. Computational biology is speeding up preclinical work like crazy. I'd definitely follow what DeepMind and Moderna are publishing - they're doing some seriously cool boundary-pushing research that'll probably shape where everything's headed.

Dude, you can basically skip testing thousands of random molecules by using AI to predict which ones will actually work. Machine learning looks at molecular structures and tells you about toxicity and side effects before you waste time in the lab. The accuracy is getting scary good, honestly. Plus you can mine genomic data to find totally new drug targets or figure out if existing meds work for other diseases. Just make sure your data doesn't suck first - you know how that goes. Oh, and drug repurposing is probably the fastest win if you're just getting started.

Honestly, CAR-T therapies are crushing it for blood cancers right now. Ozempic and those GLP-1 drugs completely flipped diabetes/obesity treatment on its head. mRNA vaccines obviously had their moment with COVID, but that tech's going places. CRISPR's finally letting us tackle genetic diseases that were basically untouchable before. And AI is speeding up drug discovery like crazy - DeepMind can predict protein structures in hours instead of years, which is nuts. If you're in pharma, definitely watch the AI partnerships happening. Oh, and personalized medicine stuff too. That's where everything's moving.